0001477932-21-009122.txt : 20211210 0001477932-21-009122.hdr.sgml : 20211210 20211210160558 ACCESSION NUMBER: 0001477932-21-009122 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211208 FILED AS OF DATE: 20211210 DATE AS OF CHANGE: 20211210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TERRELL JASON BRADLEY MD CENTRAL INDEX KEY: 0001567531 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36833 FILM NUMBER: 211485315 MAIL ADDRESS: STREET 1: 13215 BEE CAVE PARKWAY, SUITE 125, STREET 2: GALLERIA OAKS B CITY: AUSTIN STATE: TX ZIP: 78738 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VOLITIONRX LTD CENTRAL INDEX KEY: 0000093314 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911949078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 13215 BEE CAVE PARKWAY STREET 2: GALLERIA OAKS B, SUITE 125 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 1 (646) 650-1351 MAIL ADDRESS: STREET 1: 13215 BEE CAVE PARKWAY STREET 2: GALLERIA OAKS B, SUITE 125 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: STANDARD CAPITAL CORP DATE OF NAME CHANGE: 19990812 4 1 form4.xml FORM 4 X0306 4 2021-12-08-05:00 false 0000093314 VOLITIONRX LTD VNRX 0001567531 TERRELL JASON BRADLEY MD 13215 BEE CAVE PARKWAY, SUITE 125, GALLERIA OAKS B AUSTIN TX 78738 false true false false Chief Medical Officer Stock Option (Right to Buy) 3.60 2021-12-08-05:00 4 D false 55000 D 2021-04-13-05:00 2026-04-13-05:00 Common Stock 55000 0 D Stock Option (Right to Buy) 3.60 2021-12-08-05:00 4 A false 55000 A 2021-04-13-05:00 2030-04-13-05:00 Common Stock 55000 55000 D Stock Option (Right to Buy) 3.60 2021-12-08-05:00 4 D false 5000 D 2021-04-13-05:00 2026-04-13-05:00 Common Stock 5000 0 I By Spouse Stock Option (Right to Buy) 3.60 2021-12-08-05:00 4 A false 5000 A 2021-04-13-05:00 2030-04-13-05:00 Common Stock 5000 5000 I By Spouse The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). The reported transactions involved an amendment of outstanding options granted to the reporting person's wife, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). /s/ Jason Terrell MD 2021-12-10-05:00